Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
V-domain immunoglobulin suppressor of T-cell activation (VISTA) is a negative immune-checkpoint protein that suppresses T-cell responses. To determine whether VISTA synergizes with another immune-checkpoint, programmed death 1 (PD-1), this study characterizes the immune responses in VISTA-deficient, PD-1-deficient (KO) mice and VISTA/PD-1 double KO mice. Chronic inflammation and spontaneous activation of T cells were observed in both single KO mice, demonstrating their nonredundancy. However, the VISTA/PD-1 double KO mice exhibited significantly higher levels of these phenotypes than the single KO mice. When bred onto the 2D2 T-cell receptor transgenic mice, which are predisposed to development of inflammatory autoimmune disease in the CNS, the level of disease penetrance was significantly enhanced in the double KO mice compared with in the single KO mice. Consistently, the magnitude of T-cell response toward foreign antigens was synergistically higher in the VISTA/PD-1 double KO mice. A combinatorial blockade using monoclonal antibodies specific for VISTA and PD-L1 achieved optimal tumor-clearing therapeutic efficacy. In conclusion, our study demonstrates the nonredundant role of VISTA that is distinct from the PD-1/PD-L1 pathway in controlling T-cell activation. These findings provide the rationale to concurrently target VISTA and PD-1 pathways for treating T-cell-regulated diseases such as cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it acts through a non-redundant pathway to exert immunosuppressive effects on T cells (Liu et al., 2015)”
From Hallmarks of response, resistance, and toxicity to immune checkpoint blockade (2021) · cites this paper as Liu et al., 2015
Citations
Cites
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 4×
“PD-1 binds to two ligands, PD-ligand 1 (L1) and PD-L2 (12, 13).”
BackgroundInfluentialFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 5×
“Although neither PD-L1 nor PD-L2 KO mice develop overt organ-specific autoimmune disease, PD-L1 genetic deficiency exacerbates disease in the EAEmodel, as well as impairs fetomaternal tolerance (14, 15).”
MethodInfluentialEnhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Molecular mechanisms of T cell co-stimulation and co-inhibition
Chen, L., & Flies, D. B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3405 · Cited by 3,114
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955 · cited 4×
“PD-1 binds to two ligands, PD-ligand 1 (L1) and PD-L2 (12, 13).”
InfluentialTivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Lymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766 · cited 2×
“For example, CTLA-4 KO mice die of young age because of overwhelming lymphoproliferative disease and inflammation (8, 9).”
BackgroundNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749 · cited 3×
“Our cohoused PD-1 KO mice also developed accumulation of spontaneously activated T cells and chronic inflammation in multiple organs but failed to develop arthritis or other previously reported autoimmune phenotypes (10).”
BackgroundGreenwald, R. J., Freeman, G. J., & Sharpe, A. H. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115611 · Cited by 2,318 · cited 7×
“Because both VISTA and PD-L1 are highly expressed on CD11b+ myeloid APCs (2, 3), we hypothesize that a combined deficiency of VISTA and PD-L1 on APCs maximally enhances T-cell activation.”
BackgroundInfluentialTargeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
Autoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Chemnitz, J. M., Parry, R. V., Nichols, K. E., June, C. H., & Riley, J. L. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.2.945 · Cited by 1,246 · cited 1×
“phosphatase (SHP)-1/2 to down-regulate TCR signaling (33, 34).”
BackgroundTissue expression of PD-L1 mediates peripheral T cell tolerance
Keir, M. E., Liang, S. C., Guleria, I., Latchman, Y. E., Qipo, A., Albacker, L. A., Koulmanda, M., Freeman, G. J., Sayegh, M. H., & Sharpe, A. H. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20051776 · Cited by 1,211
Self-citationCooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858 · cited 3×
“A combinatorial antibody-mediated blockade of both PD-1 and TIM3 results in optimal T-cell responses against cancer, as well as during chronic viral infection (18, 19).”
BackgroundBettelli, E., Pagany, M., Weiner, H. L., Linington, C., Sobel, R. A., & Kuchroo, V. K. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021603 · Cited by 825
Sheppard, K.-A., Fitz, L. J., Lee, J. M., Benander, C., George, J. A., Wooters, J., Qiu, Y., Jussif, J. M., Carter, L. L., Wood, C. R., et al. (2004) · FEBS Letters · doi:10.1016/j.febslet.2004.07.083 · Cited by 791
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Self-citationHolmgaard, R. B., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 634
Spranger, S., Koblish, H. K., Horton, B., Scherle, P. A., Newton, R., & Gajewski, T. F. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-2-3 · Cited by 552
VISTA is an immune checkpoint molecule for human T cells
Lines, J. L., Pantazi, E., Mak, J., Sempere, L. F., Wang, L., O'Connell, S., Ceeraz, S., Suriawinata, A. A., Yan, S., Ernstoff, M. S., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1504 · Cited by 510
Self-citationVISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Self-citationKlebanoff, C. A., Khong, H. T., Antony, P. A., Palmer, D. C., & Restifo, N. P. (2005) · Trends in Immunology · doi:10.1016/j.it.2004.12.003 · Cited by 469
A critical role for the programmed death ligand 1 in fetomaternal tolerance
Guleria, I., Khosroshahi, A., Ansari, M. J., Habicht, A., Azuma, M., Yagita, H., Noelle, R. J., Coyle, A., Mellor, A. L., Khoury, S. J., et al. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050019 · Cited by 439
Self-citationWang, L., Pino-Lagos, K., de Vries, V. C., Guleria, I., Sayegh, M. H., & Noelle, R. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710441105 · Cited by 389
Self-citationA mouse knockout library for secreted and transmembrane proteins
Tang, T., Li, L., Tang, J., Li, Y., Lin, W. Y., Martin, F., Grant, D., Solloway, M., Parker, L., Ye, W., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1644 · Cited by 336
PD-1 and LAG-3 inhibitory co-receptors act synergistically to prevent autoimmunity in mice
Okazaki, T., Okazaki, I.-M., Wang, J., Sugiura, D., Nakaki, F., Yoshida, T., Kato, Y., Fagarasan, S., Muramatsu, M., Eto, T., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100466 · Cited by 324
Coinhibitory receptor PD-1H preferentially suppresses CD4+ T cell–mediated immunity
Flies, D. B., Han, X., Higuchi, T., Zheng, L., Sun, J., Ye, J. J., & Chen, L. (2014) · Journal of Clinical Investigation · doi:10.1172/jci74589 · Cited by 282
Flies, D. B., Wang, S., Xu, H., & Chen, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100660 · Cited by 249
New insights into the T cell synapse from single molecule techniques
Dustin, M. L., & Depoil, D. (2011) · Nature Reviews Immunology · doi:10.1038/nri3066 · Cited by 204
Wang, L., Le Mercier, I., Putra, J., Chen, W., Liu, J., Schenk, A. D., Nowak, E. C., Suriawinata, A. A., Li, J., & Noelle, R. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407447111 · Cited by 195
Self-citationPentcheva-Hoang, T., Chen, L., Pardoll, D. M., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708767104 · Cited by 112
B7-H4–deficient mice display augmented neutrophil-mediated innate immunity
Zhu, G., Augustine, M. M., Azuma, T., Luo, L., Yao, S., Anand, S., Rietz, A. C., Huang, J., Xu, H., Flies, A. S., et al. (2009) · Blood · doi:10.1182/blood-2008-01-133223 · Cited by 79
Sequential Cooperation of CD2 and CD48 in the Buildup of the Early TCR Signalosome
Muhammad, A., Schiller, H. B., Förster, F., Eckerstorfer, P., Geyeregger, R., Leksa, V., Zlabinger, G. J., Sibilia, M. C., Sonnleitner, A., Paster, W., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800691 · Cited by 45
Lysechko, T. L., & Ostergaard, H. L. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.12.7807 · Cited by 26
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
Wei, S. C., Duffy, C. R., & Allison, J. P. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0367 · Cited by 3,088
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Coinhibitory Pathways in Immunotherapy for Cancer
Baumeister, S. H., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 910
Integrative Molecular Characterization of Malignant Pleural Mesothelioma
Hmeljak, J., Sanchez-Vega, F., Hoadley, K. A., Shih, J., Stewart, C., Heiman, D., Tarpey, P., Danilova, L., Drill, E., Gibb, E. A., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0804 · Cited by 618
Self-citation
Metadata
- Authors
- Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., & Wang, L.
- Affiliations
- China Pharmaceutical University (CN)
- Medical College of Wisconsin (US)
- Department of Pathology and
- Dartmouth College (US)
- Brigham and Women's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2015-05-11
- Volume
- 112
- Issue
- 21
- Pages
- 6682-6687
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC4450438
- OpenAlex
- W1572739876
- Cited by
- 374
- References
- 36
- Citations by year
- 2026: 18 · 2025: 50 · 2024: 45 · 2023: 44 · 2022: 40 · 2021: 43 · 2020: 34 · 2019: 28 · 2018: 31 · 2017: 24 · 2016: 14 · 2015: 3
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- HHS | NIH | National Cancer Institute (1R01CA164225)
- U.S. Department of Defense (CA130351)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- VISTA, PD-1, immune checkpoint, T cell activation, chronic inflammation, autoimmune encephalomyelitis, PD-L1 blockade, cancer immunotherapy
- MeSH terms
- Animals, Antibodies, Monoclonal, Antigens, Female, Immune Tolerance, Ligands, Lymphocyte Activation, Male, Membrane Proteins, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, T-Lymphocytes, Mice, Knockout, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.